Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders

Ryuzo Ohno; Tomomitsu Hotta; Michinori Ogura; Kazunori Ohnishi; Takehisa Morishita; Takashi Murate; Masao Okumura; Mitsune Tanimoto; Chikako Inoue; Motohiro Hamaguchi; Atsushi Ichikawa; Seiichi Gotoh; Hidehiko Saito; Noriyuki Hirabayashi; Keitaro Tsushita; Hideo Takeyama; Hironori Yamada; Takaaki Takeo; Shozo Yokomaku; Kanji Ogata; Toshimasa Nagai; Harumitsu Mizuno; Hisami Yamao; Kyuzo Suzuki; Takae Kataoka; Yutaka Hirota; Masao Tanaka; Yasumitsu Nakaide; Yoshihisa Fujiwara; Takuhei Murase; Hirokazu Nagai; Jiro Inagaki; Kouichi Nakamura; Noboru Tanabe; Makoto Utsumi

doi:10.11553/antibiotics1968b.42.1713

Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders

Ryuzo Ohno, Tomomitsu Hotta, Michinori Ogura, Kazunori Ohnishi, Takehisa Morishita, Takashi Murate, Masao Okumura, Mitsune Tanimoto, Chikako Inoue, Motohiro Hamaguchi, Atsushi Ichikawa, Seiichi Gotoh, Hidehiko Saito, Noriyuki Hirabayashi, Keitaro Tsushita, Hideo Takeyama, Hironori Yamada, Takaaki Takeo, Shozo Yokomaku, Kanji OgataToshimasa Nagai, Harumitsu Mizuno, Hisami Yamao, Kyuzo Suzuki, Takae Kataoka, Yutaka Hirota, Masao Tanaka, Yasumitsu Nakaide, Yoshihisa Fujiwara, Takuhei Murase, Hirokazu Nagai, Jiro Inagaki, Kouichi Nakamura, Noboru Tanabe, Makoto Utsumi

Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Infectious episodes in 90 patients with hematological disorders were treated with sulbactam/ cefoperazone (SBT/CPZ), a new combination drug of a potent β-lactamase inhibitor, sodium sulbactam, and a third generation cephalosporin, sodium cefoperazone. Clinical responses to the SBT/CPZ regimen were excellent in 23 cases, good in 30 cases, fair in 11 cases, and poor in 26 cases. The overall efficacy rate (percentage of cases showing excellent or good responses) was 5S.9%. Efficacy rates classified according to different infections were: 80% in documented sepsis, 57.6% in suspected sepsis, 61.1% in pneumonia and 50% in other infections. One episode of side effect was encountered with redness and itching of skin. Hepatic disorders were observed in 3 cases. These adverse reactions, however, were not serious. These results indicate that SBT/CPZ has a high therapeutic efficacy to severe infections in patients with hematological disorders.

Original language	English
Pages (from-to)	1713-1719
Number of pages	7
Journal	The Japanese journal of antibiotics
Volume	42
Issue number	8
DOIs	https://doi.org/10.11553/antibiotics1968b.42.1713
Publication status	Published - 1989

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.42.1713

Cite this

Ohno, R., Hotta, T., Ogura, M., Ohnishi, K., Morishita, T., Murate, T., Okumura, M., Tanimoto, M., Inoue, C., Hamaguchi, M., Ichikawa, A., Gotoh, S., Saito, H., Hirabayashi, N., Tsushita, K., Takeyama, H., Yamada, H., Takeo, T., Yokomaku, S., ... Utsumi, M. (1989). Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders. The Japanese journal of antibiotics, 42(8), 1713-1719. https://doi.org/10.11553/antibiotics1968b.42.1713

Ohno, R, Hotta, T, Ogura, M, Ohnishi, K, Morishita, T, Murate, T, Okumura, M, Tanimoto, M, Inoue, C, Hamaguchi, M, Ichikawa, A, Gotoh, S, Saito, H, Hirabayashi, N, Tsushita, K, Takeyama, H, Yamada, H, Takeo, T, Yokomaku, S, Ogata, K, Nagai, T, Mizuno, H, Yamao, H, Suzuki, K, Kataoka, T, Hirota, Y, Tanaka, M, Nakaide, Y, Fujiwara, Y, Murase, T, Nagai, H, Inagaki, J, Nakamura, K, Tanabe, N & Utsumi, M 1989, 'Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders', The Japanese journal of antibiotics, vol. 42, no. 8, pp. 1713-1719. https://doi.org/10.11553/antibiotics1968b.42.1713

@article{b92888110e574fb78b722fe3cb6f9877,

title = "Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders",

abstract = "Infectious episodes in 90 patients with hematological disorders were treated with sulbactam/ cefoperazone (SBT/CPZ), a new combination drug of a potent β-lactamase inhibitor, sodium sulbactam, and a third generation cephalosporin, sodium cefoperazone. Clinical responses to the SBT/CPZ regimen were excellent in 23 cases, good in 30 cases, fair in 11 cases, and poor in 26 cases. The overall efficacy rate (percentage of cases showing excellent or good responses) was 5S.9%. Efficacy rates classified according to different infections were: 80% in documented sepsis, 57.6% in suspected sepsis, 61.1% in pneumonia and 50% in other infections. One episode of side effect was encountered with redness and itching of skin. Hepatic disorders were observed in 3 cases. These adverse reactions, however, were not serious. These results indicate that SBT/CPZ has a high therapeutic efficacy to severe infections in patients with hematological disorders.",

author = "Ryuzo Ohno and Tomomitsu Hotta and Michinori Ogura and Kazunori Ohnishi and Takehisa Morishita and Takashi Murate and Masao Okumura and Mitsune Tanimoto and Chikako Inoue and Motohiro Hamaguchi and Atsushi Ichikawa and Seiichi Gotoh and Hidehiko Saito and Noriyuki Hirabayashi and Keitaro Tsushita and Hideo Takeyama and Hironori Yamada and Takaaki Takeo and Shozo Yokomaku and Kanji Ogata and Toshimasa Nagai and Harumitsu Mizuno and Hisami Yamao and Kyuzo Suzuki and Takae Kataoka and Yutaka Hirota and Masao Tanaka and Yasumitsu Nakaide and Yoshihisa Fujiwara and Takuhei Murase and Hirokazu Nagai and Jiro Inagaki and Kouichi Nakamura and Noboru Tanabe and Makoto Utsumi",

year = "1989",

doi = "10.11553/antibiotics1968b.42.1713",

language = "English",

volume = "42",

pages = "1713--1719",

journal = "The Japanese journal of antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "8",

}

TY - JOUR

T1 - Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders

AU - Ohno, Ryuzo

AU - Hotta, Tomomitsu

AU - Ogura, Michinori

AU - Ohnishi, Kazunori

AU - Morishita, Takehisa

AU - Murate, Takashi

AU - Okumura, Masao

AU - Tanimoto, Mitsune

AU - Inoue, Chikako

AU - Hamaguchi, Motohiro

AU - Ichikawa, Atsushi

AU - Gotoh, Seiichi

AU - Saito, Hidehiko

AU - Hirabayashi, Noriyuki

AU - Tsushita, Keitaro

AU - Takeyama, Hideo

AU - Yamada, Hironori

AU - Takeo, Takaaki

AU - Yokomaku, Shozo

AU - Ogata, Kanji

AU - Nagai, Toshimasa

AU - Mizuno, Harumitsu

AU - Yamao, Hisami

AU - Suzuki, Kyuzo

AU - Kataoka, Takae

AU - Hirota, Yutaka

AU - Tanaka, Masao

AU - Nakaide, Yasumitsu

AU - Fujiwara, Yoshihisa

AU - Murase, Takuhei

AU - Nagai, Hirokazu

AU - Inagaki, Jiro

AU - Nakamura, Kouichi

AU - Tanabe, Noboru

AU - Utsumi, Makoto

PY - 1989

Y1 - 1989

N2 - Infectious episodes in 90 patients with hematological disorders were treated with sulbactam/ cefoperazone (SBT/CPZ), a new combination drug of a potent β-lactamase inhibitor, sodium sulbactam, and a third generation cephalosporin, sodium cefoperazone. Clinical responses to the SBT/CPZ regimen were excellent in 23 cases, good in 30 cases, fair in 11 cases, and poor in 26 cases. The overall efficacy rate (percentage of cases showing excellent or good responses) was 5S.9%. Efficacy rates classified according to different infections were: 80% in documented sepsis, 57.6% in suspected sepsis, 61.1% in pneumonia and 50% in other infections. One episode of side effect was encountered with redness and itching of skin. Hepatic disorders were observed in 3 cases. These adverse reactions, however, were not serious. These results indicate that SBT/CPZ has a high therapeutic efficacy to severe infections in patients with hematological disorders.

AB - Infectious episodes in 90 patients with hematological disorders were treated with sulbactam/ cefoperazone (SBT/CPZ), a new combination drug of a potent β-lactamase inhibitor, sodium sulbactam, and a third generation cephalosporin, sodium cefoperazone. Clinical responses to the SBT/CPZ regimen were excellent in 23 cases, good in 30 cases, fair in 11 cases, and poor in 26 cases. The overall efficacy rate (percentage of cases showing excellent or good responses) was 5S.9%. Efficacy rates classified according to different infections were: 80% in documented sepsis, 57.6% in suspected sepsis, 61.1% in pneumonia and 50% in other infections. One episode of side effect was encountered with redness and itching of skin. Hepatic disorders were observed in 3 cases. These adverse reactions, however, were not serious. These results indicate that SBT/CPZ has a high therapeutic efficacy to severe infections in patients with hematological disorders.

UR - http://www.scopus.com/inward/record.url?scp=0024433137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024433137&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.42.1713

DO - 10.11553/antibiotics1968b.42.1713

M3 - Article

C2 - 2810734

AN - SCOPUS:0024433137

SN - 0368-2781

VL - 42

SP - 1713

EP - 1719

JO - The Japanese journal of antibiotics

JF - The Japanese journal of antibiotics

IS - 8

ER -

Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this